Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States
These results highlight the importance of initiating timely treatment for PBC to reduce HRU and medical costs. The findings also demonstrate the need for novel, more effective PBC treatments.
Authors
- Dongni Ye (ORCID: https://orcid.org/0000-0002-0355-0636)
- Shravanthi M. Seshasayee (ORCID: https://orcid.org/0000-0002-1692-7121)
- Nisreen Shamseddine (ORCID: https://orcid.org/0000-0001-8068-7786)
- Kris V. Kowdley (ORCID: https://orcid.org/0000-0002-8553-3652)
- Hongbo Yang (ORCID: https://orcid.org/0000-0003-0753-1931)
- Jingyi Chen (ORCID: https://orcid.org/0009-0007-0141-2241)
- Su Zhang (ORCID: https://orcid.org/0000-0002-9322-5115)
- Siva Kumar
Institutions
- Ipsen (France) (FR)
- Cornell University (US)
- Liver Institute Northwest (US)
- Ipsen (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1007/s12325-025-03439-6
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ipsen